Mitochondrial Protein HSG (Mfn-2) Is A Primary Mediator of Oxidative Apoptosis

线粒体蛋白 HSG (Mfn-2) 是氧化性细胞凋亡的主要介质

基本信息

  • 批准号:
    7732187
  • 负责人:
  • 金额:
    $ 37.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

Programmed cell death, or apoptosis, is important for the development of most organs also for adult tissue homeostasis and remodeling. However, an inexorable loss of terminally differentiated heart muscle cells is a crucial causal factor for heart failure, the current leading cause of death in developed countries. Here, we demonstrate that HSG (also named mitofusin-2), a mitochondria protein, is a major determinant of oxidative stress-mediated cardiomyocyte apoptosis. Myocardial infarction profoundly elevates endogenous HSG expression and myocyte apoptosis in vivo via a reactive oxygen species (ROS)-dependent mechanism. Similarly, oxidative stress with H2O2 concurrently increases HSG expression and apoptosis in cultured rat cardiomyocytes. Furthermore, adenoviral gene transfer-mediated overexpression of HSG is sufficient to suppress both basal and serum-stimulated Akt activation, and triggers robust cardiomyocyte apoptosis. The HSG-induced apoptosis is fully abrogated by inhibition of caspase-9 but not caspase-8, and by expression of a constitutively active PI3K mutant to activate Akt or a mitochondrial antiapoptotic protein, Bcl-xL, indicating that HSG promotes cardiomyocytes apoptosis via inhibition of the PI3K-Akt cell survival signaling and the resultant activation of the primary mitochondrial apoptotic pathway. Importantly, siRNA-mediated HSG silencing protects cells against oxidative stress-induced apoptosis. The present results indicate that cardiac HSG functions as a major determinant of heart muscle cell apoptosis in response to ischemia and oxidative stress, via inhibiting the primary cell survival signal, Akt, resulting in activation of the mitochondrial cell death pathway. Importantly, increased cardiac HSG expression is both necessary and sufficient for oxidative stress-induced heart muscle cell apoptosis, suggesting that HSG deregulation may be a crucial pathogenic element and a promising therapeutic target for heart failure (Shen et al., J. Biol. Chem. 282:23354-23361, 2007) Additionally, in vascular smooth muscle cells (VSMCs), HSG functions as a powerful cell proliferation suppressor (Chen et al. Nature Cell Biology, 6:872-883, 2004). When overexpressed, HSG triggers VSMC apoptosis (Guo et al., Circ. Res. 101:1113-22, 2007). First, multiple death-inducing stimuli, including oxidative stress with H2O2, inhibition of PKC with staurosporine, activation of PKA with forskolin, and serum deprivation, concurrently elevated Mfn-2 expression and induced VSMC apoptosis. Second, overexpression of HSG triggered apoptosis of VSMCs in culture and in balloon-injured rat carotid arteries as well, thus contributing to HSG-mediated prevention of neointima formation after angioplasty, while HSG silencing protected VSMCs against H2O2 or HSG overexpression induced apoptosis, indicating upregulation of HSG is necessary and sufficient for oxidative stress mediated VSMC apoptosis. Finally, HSG proapoptotic effect was independent of its role in mitochondrial fusion, but mediated by activation of the mitochondrial apoptotic pathway. The concurrent antiproliferative and proapoptotic effects mark HSG as a potential therapeutic target in treating cardiovascular proliferative disorders, because overgrowth of VSMCs is a pivotal etiological factor in the development of atherosclerosis and restenosis after angioplasty.
程序性细胞死亡或凋亡对于大多数器官的发育以及成体组织的稳态和重塑都是重要的。 然而,终末分化的心肌细胞的不可阻挡的损失是心力衰竭的关键原因,心力衰竭是目前发达国家的主要死亡原因。在这里,我们证明,HSG(也称为mitofusin-2),线粒体蛋白,是氧化应激介导的心肌细胞凋亡的主要决定因素。心肌梗死通过活性氧依赖性机制显著提高内源性HSG表达和心肌细胞凋亡。同样,氧化应激与H2 O2同时增加HSG的表达和细胞凋亡在培养的大鼠心肌细胞。此外,腺病毒基因转移介导的HSG过表达足以抑制基础和血清刺激的Akt激活,并引发强大的心肌细胞凋亡。HSG诱导的细胞凋亡通过抑制半胱天冬酶-9而不是半胱天冬酶-8,以及通过表达组成型活性PI 3 K突变体来激活Akt或线粒体抗凋亡蛋白Bcl-xL而完全消除,这表明HSG通过抑制PI 3 K-Akt促进心肌细胞凋亡细胞生存信号传导和由此产生的主要线粒体凋亡途径的激活。重要的是,siRNA介导的HSG沉默保护细胞免受氧化应激诱导的凋亡。目前的研究结果表明,心脏HSG功能作为心肌细胞凋亡的主要决定因素,在缺血和氧化应激反应,通过抑制主要的细胞存活信号,Akt,导致线粒体细胞死亡途径的激活。重要的是,增加的心脏HSG表达对于氧化应激诱导的心肌细胞凋亡是必要的和足够的,表明HSG失调可能是心力衰竭的关键致病因素和有希望的治疗靶点(Shen et al.,282:23354-23361,2007) 此外,在血管平滑肌细胞(VSMC)中,HSG作为强有力的细胞增殖抑制剂发挥作用(Chen等人,Nature Cell Biology,6:872-883,2004)。当过表达时,HSG触发VSMC凋亡(Guo等人,Circ. Res. 101:1113-22,2007)。 首先,多种死亡诱导刺激,包括氧化应激与H2 O2,抑制PKC与staurosporine,激活PKA与forskolin,和血清剥夺,同时升高Mfn-2的表达和诱导VSMC凋亡。第二,HSG的过表达触发了培养物和球囊损伤大鼠颈动脉中VSMC的凋亡,从而有助于HSG介导的血管成形术后新生内膜形成的预防,而HSG沉默保护VSMC免受H2 O2或HSG过表达诱导的凋亡,表明HSG的上调对于氧化应激介导的VSMC凋亡是必要且充分的。最后,HSG的促凋亡作用是独立的线粒体融合的作用,但介导的线粒体凋亡途径的激活。同时抗增殖和促凋亡作用标志着HSG作为治疗心血管增殖性疾病的潜在治疗靶点,因为VSMCs的过度生长是动脉粥样硬化和血管成形术后再狭窄发展的关键病因因素。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rui-Ping Xiao其他文献

Rui-Ping Xiao的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rui-Ping Xiao', 18)}}的其他基金

CaMKII-dB and CaMKII-dC Oppositely Regulate Cardiomyocyte viability
CaMKII-dB 和 CaMKII-dC 相反地调节心肌细胞活力
  • 批准号:
    7591974
  • 财政年份:
  • 资助金额:
    $ 37.94万
  • 项目类别:
Pi3k Gs Signal Control During B2-adrenergic stimulation
B2 肾上腺素能刺激期间的 Pi3k Gs 信号控制
  • 批准号:
    6674194
  • 财政年份:
  • 资助金额:
    $ 37.94万
  • 项目类别:
Intracellular Acidosis-Activated p38 MAPK & Hypoxia
细胞内酸中毒激活的 p38 MAPK
  • 批准号:
    6969624
  • 财政年份:
  • 资助金额:
    $ 37.94万
  • 项目类别:
Cardiac Excitation-Contraction Coupling by p38 MAPK
p38 MAPK 的心脏兴奋-收缩耦合
  • 批准号:
    6815451
  • 财政年份:
  • 资助金额:
    $ 37.94万
  • 项目类别:
B-Arrestin2 Is Required for BAR Resensitization But Not its Desensitization
B-Arrestin2 是 BAR 重新敏化所必需的,但不是其脱敏所必需的
  • 批准号:
    7732333
  • 财政年份:
  • 资助金额:
    $ 37.94万
  • 项目类别:
B-Arrestin2 Is Required for BAR Resensitization But Not
B-Arrestin2 是 BAR 重新敏化所必需的,但并非如此
  • 批准号:
    7327091
  • 财政年份:
  • 资助金额:
    $ 37.94万
  • 项目类别:
B-Arrestin2 Is Required for BAR Resensitization But Not its Desensitization
B-Arrestin2 是 BAR 重新敏化所必需的,但不是其脱敏所必需的
  • 批准号:
    7592069
  • 财政年份:
  • 资助金额:
    $ 37.94万
  • 项目类别:
Mitochondrial Protein HSG Is a Major Determinant of Oxid
线粒体蛋白 HSG 是氧化的主要决定因素
  • 批准号:
    7327023
  • 财政年份:
  • 资助金额:
    $ 37.94万
  • 项目类别:
Dysregulation of HSG Triggers Proliferative Disorders
HSG 失调会引发增殖性疾病
  • 批准号:
    6968763
  • 财政年份:
  • 资助金额:
    $ 37.94万
  • 项目类别:
Suppression of Beta-arrestin1 Phosphorylation and Function by Beta-arrestin2
Beta-arrestin2 对 Beta-arrestin1 磷酸化和功能的抑制
  • 批准号:
    7964066
  • 财政年份:
  • 资助金额:
    $ 37.94万
  • 项目类别:

相似海外基金

Development of a balloon angioplasty catheter capable of simultaneous endovascular delivery of liquid therapeutic agents into the vascular wall
开发能够同时将液体治疗剂血管内输送到血管壁的球囊血管成形术导管
  • 批准号:
    10324960
  • 财政年份:
    2021
  • 资助金额:
    $ 37.94万
  • 项目类别:
Simplified Transfemoral Carotid Angioplasty and Stenting Under FlowReversal Using a Novel Combination Access Sheath/Balloon System
使用新型组合通路鞘/球囊系统在血流逆转下简化经股颈动脉血管成形术和支架置入术
  • 批准号:
    10081007
  • 财政年份:
    2020
  • 资助金额:
    $ 37.94万
  • 项目类别:
Balloon Angioplasty Inflation Device
球囊血管成形术充气装置
  • 批准号:
    10019316
  • 财政年份:
    2017
  • 资助金额:
    $ 37.94万
  • 项目类别:
Elucidation of appropriate patients for percutaneous transluminal renal angioplasty treatment
阐明适合经皮腔内肾血管成形术治疗的患者
  • 批准号:
    17K09743
  • 财政年份:
    2017
  • 资助金额:
    $ 37.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a Novel Angioplasty Catheter for Treatment of Calcified Arteries
开发用于治疗钙化动脉的新型血管成形术导管
  • 批准号:
    MR/P026850/1
  • 财政年份:
    2017
  • 资助金额:
    $ 37.94万
  • 项目类别:
    Research Grant
Balloon Angioplasty Inflation Device
球囊血管成形术充气装置
  • 批准号:
    9410026
  • 财政年份:
    2017
  • 资助金额:
    $ 37.94万
  • 项目类别:
A Preclinical Trial of Therapeutic Angiogenesis Plus Angioplasty and Stenting for Renal Vascular Disease
治疗性血管生成加血管成形术和支架置入术治疗肾血管疾病的临床前试验
  • 批准号:
    9249339
  • 财政年份:
    2017
  • 资助金额:
    $ 37.94万
  • 项目类别:
Basic research about application of liposomes to prevent stenosis after angioplasty of craniocervical artery stenosis
应用脂质体预防颅颈动脉狭窄血管成形术后狭窄的基础研究
  • 批准号:
    25462205
  • 财政年份:
    2013
  • 资助金额:
    $ 37.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Utility Of Adenosine Stress Cardiac Magnetic Resonance Imaging Following ST Elevation Myocardial Infarction Post Primary Angioplasty
ST 段抬高型心肌梗死初次血管成形术后腺苷应激心脏磁共振成像的效用
  • 批准号:
    nhmrc : 1018161
  • 财政年份:
    2011
  • 资助金额:
    $ 37.94万
  • 项目类别:
    NHMRC Postgraduate Scholarships
Novel Approaches in Treatment of Vascular Injury Following Balloon Angioplasty
治疗球囊血管成形术后血管损伤的新方法
  • 批准号:
    8402612
  • 财政年份:
    2011
  • 资助金额:
    $ 37.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了